肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Nat commu：靶向新途径增强放疗和化疗效果

2015-09-08 佚名 生物谷

RAF抗肿瘤放化疗CRAF
关注

近日，来自美国加州大学圣地亚哥分校的研究人员在国际学术期刊nature communication上发表了一项最新研究进展，他们发现了一条新的信号途径可能导致恶性肿瘤对化疗和放疗方法产生抵抗，并针对这一信号途径找到了新的靶向治疗药物。领导该项研究的Sunil Advani说道：“在此项研究之前科学家们就已经知道RAF控制着肿瘤细胞的治疗抵抗特性。而我们发现了RAF一个新的功能，并且已经清晰地知道它

近日，来自美国加州大学圣地亚哥分校的研究人员在国际学术期刊nature communication上发表了一项最新研究进展，他们发现了一条新的信号途径可能导致恶性肿瘤对化疗和放疗方法产生抵抗，并针对这一信号途径找到了新的靶向治疗药物。

领导该项研究的Sunil Advani说道：“在此项研究之前科学家们就已经知道RAF控制着肿瘤细胞的治疗抵抗特性。而我们发现了RAF一个新的功能，并且已经清晰地知道它究竟如何在许多癌症类型中发挥作用。”

在这项研究中，研究人员发现利用放疗和化疗方法治疗肿瘤会驱动PAK1介导的CRAF 338位丝氨酸磷酸化进而触发一种激酶非依赖性的DNA修复机制产生治疗抵抗。CRAF发生磷酸化会招募CHK2并促进CHK2磷酸化/激活以增强肿瘤细胞的DNA损伤应答。

根据这一发现，研究人员将CRAF的338位丝氨酸突变为天冬氨酸模拟磷酸化状态，结果表明这一突变足以诱导CRAF/CHK2发生关联促进肿瘤对放疗的抵抗，而利用一种变构的CRAF抑制剂可以增强肿瘤细胞对放疗和化疗药物的敏感性。
 
研究人员指出，靶向这一新途径可以移除肿瘤的防御机制，而开发靶向这一途径的新药物就能够在不损伤健康组织的情况下增强肿瘤细胞对放疗的敏感性，这种药物可以大大促进放疗和特定化疗药物的DNA损伤效应，最终可以实现使用更小剂量的放射或化疗药物，获得更强的抗肿瘤效果。

原文出处：

Sunil J. Advani,Maria Fernanda Camargo,et al.Kinase-independent role for CRAF-driving tumour radioresistance via CHK2.Nat commu.2015

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1953354, encodeId=ba691953354cc, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon Jul 18 13:03:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994126, encodeId=3d6b199412643, content=<a href='/topic/show?id=1d1942288b5' target=_blank style='color:#2F92EE;'>#增强放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42288, encryptionId=1d1942288b5, topicName=增强放疗)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Tue Feb 23 23:03:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880800, encodeId=76ee188080057, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 14 19:03:00 CST 2016, time=2016-02-14, status=1, ipAttribution=)]
    2016-07-18 caobinglei8079

    #新途径#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1953354, encodeId=ba691953354cc, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon Jul 18 13:03:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994126, encodeId=3d6b199412643, content=<a href='/topic/show?id=1d1942288b5' target=_blank style='color:#2F92EE;'>#增强放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42288, encryptionId=1d1942288b5, topicName=增强放疗)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Tue Feb 23 23:03:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880800, encodeId=76ee188080057, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 14 19:03:00 CST 2016, time=2016-02-14, status=1, ipAttribution=)]
    2016-02-23 tamgche

    #增强放疗#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1953354, encodeId=ba691953354cc, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon Jul 18 13:03:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994126, encodeId=3d6b199412643, content=<a href='/topic/show?id=1d1942288b5' target=_blank style='color:#2F92EE;'>#增强放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42288, encryptionId=1d1942288b5, topicName=增强放疗)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Tue Feb 23 23:03:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880800, encodeId=76ee188080057, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 14 19:03:00 CST 2016, time=2016-02-14, status=1, ipAttribution=)]
    2016-02-14 liye789132251

    #Nat#

    0